Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,556 | 124 | 99.5% |
| Education | $13.68 | 1 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $1,268 | 70 | $0 (2024) |
| ABBVIE INC. | $755.05 | 29 | $0 (2024) |
| Insmed, Inc. | $156.31 | 6 | $0 (2022) |
| ViiV Healthcare Company | $113.75 | 6 | $0 (2022) |
| Allergan, Inc. | $72.83 | 4 | $0 (2020) |
| Melinta Therapeutics, LLC | $61.51 | 4 | $0 (2020) |
| Shionogi Inc | $59.62 | 1 | $0 (2023) |
| Merck Sharp & Dohme LLC | $53.40 | 3 | $0 (2024) |
| Horizon Therapeutics plc | $28.66 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $66.87 | 3 | Gilead Sciences, Inc. ($30.00) |
| 2023 | $230.19 | 8 | Gilead Sciences, Inc. ($150.09) |
| 2022 | $661.23 | 36 | ABBVIE INC. ($259.78) |
| 2021 | $1,255 | 53 | Gilead Sciences, Inc. ($701.33) |
| 2020 | $356.41 | 25 | Gilead Sciences, Inc. ($135.89) |
All Payment Transactions
125 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 08/16/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/01/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/13/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.31 | General |
| 10/16/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.31 | General |
| 09/13/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $59.62 | General |
| Category: Infections and Infectious Diseases | ||||||
| 06/08/2023 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $118.08 | General |
| Category: HIV | ||||||
| 04/28/2023 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/21/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $9.89 | General |
| 02/09/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $3.26 | General |
| 02/01/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $4.24 | General |
| 10/04/2022 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $10.97 | General |
| Category: Respiratory | ||||||
| 09/06/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.66 | General |
| 08/05/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $10.46 | General |
| 07/27/2022 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $23.02 | General |
| Category: Respiratory | ||||||
| 07/13/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/13/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $8.26 | General |
| 07/01/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.78 | General |
| 06/29/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $9.71 | General |
| 06/08/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $7.86 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/27/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.81 | General |
| 05/11/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $7.69 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/11/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $4.28 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/20/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/20/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.55 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 745 | 1,501 | $301,215 | $119,307 |
| 2022 | 9 | 913 | 2,248 | $541,944 | $180,002 |
| 2021 | 8 | 788 | 1,991 | $485,805 | $158,859 |
| 2020 | 10 | 617 | 1,586 | $387,670 | $122,946 |
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 279 | 933 | $146,481 | $58,207 | 39.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 300 | 345 | $89,355 | $35,649 | 39.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 66 | 100 | $25,500 | $9,675 | 37.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 33 | $11,814 | $4,731 | 40.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 27 | $9,315 | $3,738 | 40.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 35 | $8,260 | $3,271 | 39.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $5,661 | $2,272 | 40.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $4,829 | $1,764 | 36.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 256 | 1,108 | $220,396 | $63,536 | 28.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 144 | 516 | $116,182 | $42,136 | 36.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 165 | 178 | $87,450 | $27,915 | 31.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 173 | 194 | $65,105 | $20,739 | 31.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 65 | 107 | $24,525 | $15,003 | 61.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 38 | 51 | $11,625 | $5,020 | 43.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 15 | 24 | $4,380 | $1,910 | 43.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 19 | $3,041 | $1,343 | 44.2% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 16 | 16 | $3,990 | $1,296 | 32.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 24 | 35 | $5,250 | $1,105 | 21.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 343 | 1,445 | $289,000 | $84,236 | 29.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 191 | 212 | $106,000 | $33,896 | 32.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 85 | 150 | $33,750 | $21,984 | 65.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 90 | 97 | $38,800 | $10,674 | 27.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 19 | 23 | $4,025 | $2,427 | 60.3% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 29 | 29 | $8,700 | $2,399 | 27.6% |
| G0181 | Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | Office | 2021 | 17 | 21 | $3,150 | $1,894 | 60.1% |
About Khine Sann
Khine Sann is a Internal Medicine healthcare provider based in Frederick, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/24/2014. The National Provider Identifier (NPI) number assigned to this provider is 1376958744.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Khine Sann has received a total of $2,570 in payments from pharmaceutical and medical device companies, with $66.87 received in 2024. These payments were reported across 125 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($2,556).
As a Medicare-enrolled provider, Sann has provided services to 3,063 Medicare beneficiaries, totaling 7,326 services with total Medicare billing of $581,114. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Student in an Organized Health Care Education/Training Program, Infectious Disease
- Location Frederick, MD
- Active Since 06/24/2014
- Last Updated 08/04/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1376958744
Products in Payments
- DALVANCE (Drug) $646.98
- Biktarvy (Drug) $303.48
- Arikayce (Drug) $156.31
- AVYCAZ (Drug) $120.07
- DOVATO (Drug) $113.75
- Epclusa (Drug) $97.49
- Orbactiv (Drug) $61.51
- TEFLARO (Drug) $60.83
- Fetroja (Drug) $59.62
- Veklury (Drug) $32.56
- DIFICID (Drug) $20.71
- ISENTRESS (Drug) $19.17
- RAYOS (Drug) $14.66
- ACTIMMUNE (Drug) $14.00
- PREVYMIS (Drug) $13.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Frederick
Dr. Craig Washington, Md, MD
Internal Medicine — Payments: $224,755
Rohan Rengen, D.o, D.O
Internal Medicine — Payments: $38,295
Sibte Kazmi, Md, MD
Internal Medicine — Payments: $14,311
Mouhamad Bazzi, Md, MD
Internal Medicine — Payments: $14,055
Dr. Syed Haque, M.d, M.D
Internal Medicine — Payments: $13,568
Daniel Daniels, M.d, M.D
Internal Medicine — Payments: $11,052